paltusotine
Phase 3 Initiation: Oral Paltusotine Challenging the Injectable Standard in Carcinoid Syndrome
Paltusotine aims to replace depot octreotide and lanreotide injections with oral daily dosing for carcinoid syndrome. The SST2 agonist targets the same pathway while eliminating the burden of clinic-administered shots.